
On 18 April 2024, Gnosis by Lesaffre and Medience completed an exclusive distribution agreement for mineral yeast, reinforcing their commitment to quality in Japan.
Strengthening Commitment to Quality & Innovation
Gnosis by Lesaffre and Medience have solidified their partnership with the signing of an exclusive distribution agreement for mineral yeasts after five years of collaboration. This agreement underscores their shared dedication to providing high-quality products to customers in Japan. Gnosis’s mineral yeast products are highly regarded for their quality, benefiting from Lesaffre’s extensive history and expertise in fermentation, which ensures that customers in Japan have access to top-notch mineral yeast products.
A Shared Vision for Sustainability & Excellence
Marco Atanassi, Asia Pacific & China Sales Director at Gnosis, emphasized the company’s commitment to sustainability and environmental responsibility in its production processes. This exclusive agreement with Medience, a company that shares their values, allows Gnosis to bring their high-quality mineral yeast products to the Japanese market. Gnosis’s production facilities maintain ISO certifications, guaranteeing the safety and quality of their products and highlighting the company’s dedication to excellence. The company has also invested significantly in its Cedar Rapids, Iowa plant to meet the increasing demand for human nutrition and health products while prioritizing environmental sustainability and reducing CO2 emissions.
Latest news & videos

- Corporate
- Digestion & Gut
- News
- Jun 06, 2025
Biotic Live: A Successful First Edition Exploring the Power of Probiotic Yeasts
Gnosis by Lesaffre recently hosted the first edition of Biotic Live, a unique event...

- Mobility & Joint
- MyCondro®
- News
- Jun 05, 2025
Redefining Joint Health: Gnosis by Lesaffre Showcases MyCondro™ at CMA Innovation Day
At the recent Innovation Day seminar hosted by Complementary Medicines Australia (CMA), Gnosis by...

- MenaQ7®
- Mobility & Joint
- News
- Jun 02, 2025
Supplementation with Menaquinone-7 (as MenaQ7®) Slows the Progression of Coronary Artery Calcification
The first results from the VitaK-CAC Trial, “Menaquinone-7 Slows Down Progression of Coronary Artery...